NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has completed its acquisition of transplant diagnostics firm One Lambda for $925 million.
One Lambda, which had 2011 revenues of around $182 million, will become part of Thermo Fisher's Specialty Diagnostics Segment. The Canoga Park, Calif.-based firm develops tests that are used by transplant centers for tissue typing, mainly for determining compatibility between donors and recipients and for detecting the presence of antibodies that can result in transplant rejection.
Thermo Fisher had announced the deal in July, and reiterated today that it expects the deal to add between $.09 and $.11 to its 2013 adjusted EPS.
"One Lambda's tests for tissue typing and antibody detection complement our existing immunosuppressant assays, allowing us to offer a broad menu of tests across the transplant-testing workflow," Thermo Fisher Scientific President and CEO Marc Casper said in a statement.